All In Biotech

Drug Trial Radar · NCT07934121

MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer

A Phase 2 Study of Mirvetuximab Soravtansine (MIRV) in Combination With Suvemcitug for the Treatment of Folate Receptor Alpha (FRα)-Expressing Partially Platinum-Sensitive Ovarian Cancer (MISO)

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 10, 2026

Primary completion

Jun 30, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Tongji HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, single-arm, phase II study designed to evaluate the efficacy and safety of mirvetuximab soravtansine combined with suvemcitug in patients with FRα-positive partially platinum-sensitive recurrent ovarian cancer. Approximately 80 patients will be enrolled. Eligible patients must have recurrent high-grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer with FRα expression and disease recurrence occurring 6 to 12 months after completion of platinum-based chemotherapy. Participants will receive mirvetuximab soravtansine and suvemcitug every 2 weeks until disease progression, unacceptable toxicity, withdrawal of consent, or study termination. Tumor response will be assessed according to RECIST version 1.1. The primary objective is to evaluate the objective response rate (ORR). Secondary objectives include duration of response (DOR), progression-free survival (PFS), overall survival (OS), CA125 response, and safety outcomes. Exploratory analyses will assess the relationship between FRα expression, other biomarkers, and clinical outcomes.

Conditions

  • Platinum-Sensitive Recurrent Ovarian Cancer

Interventions

  • Mirvetuximab SoravtansineDrug

    Mirvetuximab soravtansine is a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody linked to the maytansinoid DM4. It is administered intravenously in combination with suvemcitug for the treatment of patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.

  • SuvemcitugDrug

    Suvemcitug is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF). In this study, suvemcitug is administered intravenously in combination with mirvetuximab soravtansine to evaluate the efficacy and safety in patients with FRα-expressing partially platinum-sensitive recurrent ovarian cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate(ORR)Time frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.